Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, March 1999, p. 471-475, Vol. 43, No. 3
The Second Department of Internal Medicine,
Received 27 August 1998/Returned for modification 1 October
1998/Accepted 4 December 1998
We evaluated the in vitro and in vivo potencies of a new lipid
nanosphere that incorporates amphotericin B (AmB), NS-718, against
Aspergillus fumigatus. The in vitro activity of NS-718 (the
MIC at which 90% of strains are inhibited [MIC90], 0.25 µg/ml) against 18 isolates of A. fumigatus was similar to
that of deoxycholate AmB (D-AmB; Fungizone; MIC90, 0.25 µg/ml), but NS-718 was more potent than liposomal AmB (L-AmB;
AmBisome; MIC90, 1.0 µg/ml). The in vivo efficacy of
NS-718 in a rat model of invasive pulmonary aspergillosis was compared
with those of D-AmB and L-AmB. A low dose (1 mg/kg of body weight) of
L-AmB was ineffective (survival rate, 0%), although equivalent doses
of D-AmB and NS-718 were more effective (survival rate, 17%). However,
a higher dose of NS-718 (3 mg/kg) was more effective (survival rate,
100%) than equivalent doses of D-AmB and L-AmB (survival rate, 0%).
To explain these differences, pharmacokinetic studies showed higher
concentrations of AmB in the plasma of rats treated with NS-718 than in
the plasma of those treated with D-AmB. Our results suggest that
NS-718, a new preparation of AmB, is a promising antifungal agent with activity against pulmonary aspergillosis.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
In Vitro and In Vivo Activities of NS-718, a New
Lipid Nanosphere Incorporating Amphotericin B, against
Aspergillus fumigatus
*
Corresponding author. Mailing address: The Second
Department of Internal Medicine, Nagasaki University School of
Medicine, Sakamoto 1-7-1, Nagasaki 852-8501, Japan. Phone:
81-95-849-7271. Fax: 81-95-849-7285. E-mail:
sk1227{at}net.nagasaki-u.ac.jp.
Antimicrobial Agents and Chemotherapy, March 1999, p. 471-475, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kakeya, H., Miyazaki, Y., Senda, H., Kobayashi, T., Seki, M., Izumikawa, K., Yanagihara, K., Yamamoto, Y., Tashiro, T., Kohno, S.
(2008). Efficacy of SPK-843, a Novel Polyene Antifungal, in Comparison with Amphotericin B, Liposomal Amphotericin B, and Micafungin against Murine Pulmonary Aspergillosis. Antimicrob. Agents Chemother.
52: 1868-1870
[Abstract] [Full Text] -
Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., Niki, Y.
(2006). Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother
57: 724-731
[Abstract] [Full Text] -
Sanchez-Brunete, J. A., Dea, M. A., Rama, S., Bolas, F., Alunda, J. M., Raposo, R., Mendez, M. T., Torrado-Santiago, S., Torrado, J. J.
(2004). Treatment of Experimental Visceral Leishmaniasis with Amphotericin B in Stable Albumin Microspheres. Antimicrob. Agents Chemother.
48: 3246-3252
[Abstract] [Full Text] -
Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., Niki, Y.
(2004). Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother
53: 311-317
[Abstract] [Full Text] -
Hossain, M. A., Maesaki, S., Razzaque, M. S., Tomono, K., Taguchi, T., Kohno, S.
(2000). Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B. J Antimicrob Chemother
46: 263-268
[Abstract] [Full Text]
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»